Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK061 minitablets pharmacokinetics in healthy adults
NCT06306872Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irpagratinib (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve at 72 hours and 1 more. Started Feb 2024; status: completed.
02
Drugs
irpagratinib
Beyond the preview
Go deeper on NCT06306872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06306872.